Revenue and Profit - The company's revenue for Q1 2024 was ¥130,725,745.26, representing a 7.69% increase compared to ¥121,392,447.24 in the same period last year[6] - Net profit attributable to shareholders decreased by 75.99% to ¥3,667,660.56 from ¥15,275,796.35 year-on-year[6] - The net profit after deducting non-recurring gains and losses fell by 95.45% to ¥625,453.36 from ¥13,739,956.83 in the previous year[6] - Basic and diluted earnings per share decreased by 78.57% to ¥0.03 from ¥0.14 year-on-year[6] - Total operating revenue for Q1 2024 was CNY 130,725,745.26, an increase of 7.9% compared to CNY 121,392,447.24 in Q1 2023[19] - Net profit for Q1 2024 was CNY 3,667,660.56, a decrease of 76.0% from CNY 15,275,796.35 in Q1 2023[21] - Earnings per share for Q1 2024 was CNY 0.03, down from CNY 0.14 in Q1 2023[21] Cash Flow - The net cash flow from operating activities was ¥9,275,848.83, down 31.58% from ¥13,556,647.25 in the same period last year[6] - The net cash flow from investment activities improved by 83.58%, amounting to -¥69,918,129.23 compared to -¥425,843,102.78 in the previous year[11] - The net cash flow from financing activities was -¥14,801,196.56, a 218.07% increase in outflow due to share repurchase expenditures[11] - The total cash inflow from investment activities was ¥148,976,301.52, while cash outflow was ¥218,894,430.75, resulting in a net cash flow of -¥69,918,129.23, compared to -¥425,843,102.78 in the previous year[24] - The cash flow from financing activities showed a net outflow of -¥14,801,196.56, compared to -¥4,653,403.39 in Q1 2023[24] - The total cash and cash equivalents at the end of Q1 2024 were ¥61,284,963.03, down from ¥335,073,505.57 at the end of Q1 2023[25] - The company received ¥146,500,000.00 from investment recoveries, an increase from ¥100,850,000.00 in the previous year[24] - The cash received from investment income was ¥1,687,172.98, compared to ¥461,082.24 in Q1 2023, indicating a significant increase[24] - The company reported a total cash inflow from operating activities of ¥133,017,248.48, slightly down from ¥136,608,000.75 in the same period last year[24] - The cash paid for purchasing goods and services was ¥37,446,599.20, compared to ¥40,629,035.33 in Q1 2023, reflecting a decrease of 5.6%[24] - The company experienced a foreign exchange impact on cash and cash equivalents of ¥1,231,484.31, contrasting with -¥1,628,971.69 in the previous year[25] - The total cash outflow from financing activities was ¥22,139,116.05, significantly higher than ¥4,653,403.39 in Q1 2023[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,450,938,940.27, a decrease of 2.44% from ¥1,487,163,922.77 at the end of the previous year[6] - The company's cash and cash equivalents decreased from ¥204,296,295.47 to ¥108,312,854.23, a decline of approximately 47%[15] - The total current assets decreased from ¥731,324,912.60 to ¥701,273,371.03, a reduction of about 4.1%[16] - Short-term borrowings increased from ¥15,921,295.25 to ¥23,258,158.74, an increase of about 46.5%[16] - The accounts payable decreased from ¥106,333,992.50 to ¥96,237,694.50, a reduction of approximately 9.5%[16] - Total liabilities as of Q1 2024 were CNY 347,585,320.30, down from CNY 369,619,256.24 in the previous quarter[20] - Total equity attributable to shareholders of the parent company was CNY 1,103,353,619.97, a decrease from CNY 1,117,544,666.53 in the previous quarter[20] Operating Costs and Expenses - The company reported a significant increase in operating costs, which rose by 33.19% to ¥103,778,044.13 from ¥77,917,655.65 year-on-year[10] - Total operating costs for Q1 2024 were CNY 135,325,810.41, up 29.5% from CNY 104,504,260.72 in the same period last year[20] - The company reported a significant increase in financial expenses, with interest expenses rising to CNY 2,410,254.65 from CNY 1,045,393.66 in the previous year[20] - Research and development expenses for Q1 2024 were CNY 11,274,826.18, an increase of 10.9% from CNY 10,163,571.92 in Q1 2023[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,397[12] - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Medical Technology Co., Ltd., holds 27.64% of shares, totaling 29,750,000 shares[12] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 39%[12] - The company has a total of 0.58% of its shares held in a repurchase account, totaling 629,300 shares[14] - The company has not reported any changes in the number of preferred shareholders or any significant changes in shareholding due to margin trading[14] Future Outlook - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[20]
泓博医药(301230) - 2024 Q1 - 季度财报